Top Biotech Picks For 2021 With The Most Upside Potential
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
davidgoldstein
4 Under-$10 Biotech Stocks With Solid Upside Potential For Aggressive Traders
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher…
With A Focus On Genomics, This Lesser-Known ETF Is Outperforming – And Now May Be The Time To Buy
The lesser-known ETF discussed in today’s article is already beating the market – up 185% year to date – and the author believes it will…
Treating Severe COVID-19 Could Be Just “The Tip Of The Iceberg” For This Biotech Up 38,000%
The small Swiss biotech firm featured in today’s article has been developing a drug that could help patients suffering from severe COVID-19 – and with…
Battle Of The “Strong Buy” Biotechs
BioXcel Therapeutics is a clinical-stage biopharmaceutical company that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. TG Therapeutics is a biopharmaceutical company…
3 Biotech Stocks Flying High In The Mid-Cap “Sweet Spot”
In regards to biotech’s bullish year, the author of today’s article notes that “The COVID-19 pandemic has put a fire under many lesser-known names, including…
Biotech Winners And Losers Out Of ASH
A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and,…
High Growth And Reasonable Risk: 2 Biotech Stocks To Consider
“In such a volatile market, it is quite difficult to find reasonably safe and high-growth biotech stocks,” acknowledges the author of today’s article. Of course,…
2 Biotech ETFs To Monitor For Potential Breakouts – And Possible Trading Plays For Both
With the global biotechnology market expected, by one estimate, to almost double from its $448 billion level last year to $833 billion by 2027, today’s…
An Options Strategy For This COVID Vaccine Play With More Room To Run
When it comes to COVID-19 vaccine manufacturers, the author of today’s article notes “While it’s no surprise that investors have already bought into these companies,…